Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation

( views:115, downloads:0 )
Author:
ZHANG Qi(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
ZHANG Rui-yan(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
SHEN Jie(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
ZHANG Jian-sheng(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
HU Jian(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
YANG Zheng-kun(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
ZHANG Xian(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
ZHENG Ai-fang(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
SHEN Wei-feng(Department of Cardiology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
Journal Title:
CHINESE MEDICAL JOURNAL
Issue:
Volume 121, Issue 23, 2008
DOI:
Key Word:
acute myocardial infarction;percutaneous coronary intervention;drug-eluting stent;renal dysfunction;prognosis

Abstract: Background Prognosis of patients with acute ST-elevation myocardial infarction (STEMI) and renal dysfunction (RD) who received primary percutaneous coronary intervention (PCI) has not been fully investigated in the drug-eluting stent (DES) era.This study aimed to evaluate the impact of admission serum creatinine level on short-term outcomes in patients with acute STEMI undergoing DES-based primary PCI.Methods Primary PCI with DES implantation was attempted in 619 consecutive STEMI patients within 12 hours of symptom onset.Among them,86 patients had a serum creatinine level >115 μmol/L on admission (RD group),and the remaining 533 patients had normal renal function (non-RD group).The primary endpoint was 30-day major adverse cardiac events (MACE,including death,non-fatal reinfarction,and target vessel revascularization),and the secondary endpoint was subacute stent thrombosis.Results Patients in the RD group were older than those in the non-RD group.There are more female patients in the RD group and they had a history of hypertension,myocardial infarction and revascularization.The occurrence rates of Killip class ≥2 (29.1% vs 18.6%,P=0.02) and multi-vessel (62.8% vs 44.5%,P=0.001) and triple vessel disease (32.6% vs 18.2%,P=0.002),in-hospital mortality (9.3% vs 3.8%,P=0.03),and MACE rate during hospitalization (17.4% vs 7.7%,P=0.006) were higher in the RD group than those in the non-RD group.At a 30-day clinical follow-up,the MACE-free survival rate was significantly reduced in the RD group (76.7% vs 89.9%,P=0.0003).Angiographic stent thrombosis occurred in 3 (3.5%) and 7 (1.3%) of patients in the RD group and non-RD group,respectively (P=0.15).Multivariate analysis revealed that the serum creatinine level≥115 μmol/L on admission was an independent predictor for MACE rate at a 30-day follow-up (Hazard ratio (HR) 3.31,95% CI 1.19-9.18,P<0.001).Conclusion Despite similar prevalence of stent thrombosis at a 30-day clinical follow-up,the short-term prognosis of STEMI patients with elevated serum creatinine on admission undergoing DES-based primary PCI remains unfavorable.

  • [1]King SB,Smith SC Jr.,Hirshfeld JW Jr.,Jacobs AK,Morrison DA,Williams DO,et al.2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines.J Am Coil Cardiol 2008; 51:172-209.
  • [2]Gurewich V.Primary percutaneous coronary intervention.N Engl J Med 2008; 358:431-433.
  • [3]Zhang Q,Shen J,Zhang RY,Qiu JP,Lu JD,Zhang Y,et al.Outcomes after primary coronary intervention with drug-eluting stent implantation in diabetic patients with acute ST elevation myocardial infarction.Chin Med J 2007; 120:1862-1867.
  • [4]Lee JH,Kim HS,Lee SW,Park JH,Choi SW,Jeong JO,et al.Prospective randomized comparison of sirolimus-versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction:pROSIT trial.Catheter Cardiovasc Interv 2008; 72:25-32.
  • [5]Kupferwasser LI,Amorn AM,Kapoor N,Lee MS,Kar S,Cercek B,et al.Comparison of drug-eluting stents with bare metal stents in unselccted patients with acute myocardial infarction.Catheter Cardiovasc Interv 2007; 70:1-8.
  • [6]Kastrati A,Dibra A,Spaulding C,Laa an G J,Menichelli M,Valgimigli M,et al.Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction.Eur Heart J 2007; 28:2706-2713.
  • [7]Anavekar NS,McMurray JJ,Velazquez F_J,Solomon SD,Kober L,Roulean JL,et al.Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.N Engl J Med 2004; 351:1285-1295.
  • [8]Wright RS,Reeder GS,Herzog CA,Albright RC,Williams BA,Dvorak DL,et al.Acute myocardial infarction and renal dysfunction:a high-risk combination.Ann Intern Med 2002;137:563-570.
  • [9]Yamaguchi J,Kasanuki H,Ishii Y,Yagi M,Nagashima M,Fujii S,et al.Serum creatinine on admission predicts long-term mortality in acute myocardial infarction patients undergoing successful primary angioplasty:data from the Heart Institute of Japan Acute Myocardial Infarction (HIJAMI)Registry.Circ J 2007; 71:1354-1359.
  • [10]Antman EM,Hand M,Armstrong PW,Bates ER,Green LA,Halasyamani LK,et al.2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coil Cardiol 2008; 51:210-247.
  • [11]Gibson CM,Karha J,Murphy SA,James D,Morrow DA,Cannon CP,et al.Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials.J Am Coil Cardiol 2003; 42:7-16.
  • [12]Cutlip DE,Windecker S,Mehran R,Boam A,Cohen DJ,van Es GA,et al.Clinical end points in coronary stent trials:a case for standardized definitions.Circulation 2007; 115:2344-2351.
  • [13]Sadeghi HM,Stone GW,Gaines CL,Mehran R,Dixon SR,Lansky AJ,et al.Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.Circulation 2003; 108:2769-2775.
  • [14]Muntner E He J,Hanun L,Loria C,Whelton PK.Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States.J Am Soc Nephrol 2002; 13:745-753.
  • [15]Freeman RV,Mehta RH,Al Badr W,Cooper JV,Kline-Rogers E,Eagle KA.Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors.J Am Coll Cardiol 2003; 41:718-724.
  • [16]Fathi RB,Gurm HS,Chew DP,Gupta R,Bhatt DL,Ellis SG.The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention.Am Heart J 2005; 150:1190-1197.
  • [17]Zhang RY,Ni JW,Zhang JS,Hu J,Yang ZK,Zhang Q,et al.Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention.Chin Meal J 2006; 119:1176-1181.
  • [18]Zhang Q,Fang YH,Zbang RY,Hu J,Yang ZK,Ni J,et al.Drug-eluting stents improve clinical outcomes in Chinese diabetic patients with de novo coronary artery disease.Chin Med J 2006; 119:1576-1579.
  • [19]Stettler C,Wandel S,Allemann S,Kastrati A,Morice MC,Schomig A,et al.Outcomes associated with drug-eluting and bare-metal stents:a collaborative network recta-analysis.Lancet 2007; 370:937-948.
  • [20]Planas-Del Viejo AM,Pomar-Domingo F,Vilar-Herrero JV,Jacas-Osborn V,Nadal-Barange M,Perez-Fernandez E.Long-term clinical and angiographic follow-up of drug-eluting stents in patients with ST-elevation acute myocardial infarction.Rev Esp Cardiol 2008; 61:360-368.
  • [21]Pasceri V,Patti G,Speciale G.Pristipino C,Richichi G,Di Sciascio G.Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction.Am Heart J 2007; 153:749-754.
  • [22]Jose P,Skali H,Anavekar N,Tomson C,Krumholz HM,Rouleau JL,et al.Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction.J Am Soc Nephrol 2006; 17:2886-2891.
  • [23]Verma A,Anavekar NS,Meris A,Thune J J,Arnold JM,Ghali JK,et al.The relationship between renal function and cardiac structure,function,and prognosis after myocardial infarction:the VALIANT Echo Study.J Am Coil Cardiol 2007; 50:1238-1245.
  • [24]Shen J,Zhang Q,Zhang RY,Zhang JS,Hu J,Yang ZK,et al.Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Coron Artery Dis 2008; 19:271-277.
  • [25]Gruberg L,Mintz GS,Mehran R,Gangas G,Lansky A J,Kent KM,et al.The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency.J Am Coil Cardio12000; 36:1542-1548.
  • [26]Yamaguchi J,Kasanuki H,Ishii Y,Yagi M,Ogawa H,Fujii SY,et al.Prognostic significance of serum creatinine concentration for in-hospital mortality in patients with acute myocardial infarction who underwent successful primary percutaneous coronary intervention (from the Heart Institute of Japan Acute Myocardial Infarction (HIJAMI) Registry).Am J Cardiol 2004; 93:1526-1528.
  • [27]Weiner DE,Tighiouart H,Stark PC,Amin MG,MacLeod B,Griffith JL,et al.Kidney disease as a risk factor for recurrent cardiovascular disease and mortality.Am J Kidney Dis 2004;44:198-206.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn